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Abstract
Background: Cardiac arrhythmia after coronary artery bypass grafting (CABG) surgery is
a common complication of cardiac surgery. The effect of serum magnesium, hypomagne-
saemia treatment and prophylactic administration of magnesium in the development and
prevention of arrhythmias is controversial and there are many different ideas. This study
evaluates the therapeutic effects of magnesium in cardiac arrhythmia after CABG surgery.
Methods: The clinical trial enrolled 250 patients who underwent CABG. Based on the ini-
tial serum levels of magnesium, patients were divided into two groups: hypomagnesium and
normomagnesium. Based on bioethics committee requirements, patients in the hypo-
magnesium group received magnesium treatments until they attained normal magnesium
blood levels. Both groups underwent CABG with normal blood levels of magnesium.
After surgery, each group was randomly divided into two subgroups: one subgroup
received a bolus dose of magnesium sulphate (30 mg/kg in 5 min) and the other subgroup
received a placebo. Subgroups were under observation in the intensive care unit for 3 days
and arrhythmias were recorded. Data from all four subgroups were analysed statistically
and interpreted.
Results: The results of this study showed that the occurrence of arrhythmia was not signiﬁ-
cantly different among subgroups (P > 0.05). There was no signiﬁcant relationship between
blood levels of magnesium and arrhythmia during the 3 days post-surgery (P > 0.05).
Conclusion: The results of this study showed that magnesium sulphate administration did
not signiﬁcantly improve the incidence of arrhythmias in hypo- and normo-magnesium
patients after CABG. There was no signiﬁcant correlation between post-operative serum
levels of magnesium and arrhythmia during 3 days.
Introduction
Cardiovascular system disorders are some of the most important
health problems. A large number of cardiac patients undergo car-
diac surgery, and coronary artery bypass grafting (CABG) is espe-
cially common. CABG is an ‘open heart surgery in which a
section of a blood vessel is grafted from the aorta to the coronary
artery to bypass the blocked section of the coronary artery and
improve the blood supply to the heart’. Nowadays, myocardial
revascularization is the most accepted operation performed by car-
diac surgeons.1,2 Because CABG is implemented widely by sur-
geons, expanding the current knowledge of this operation could
enrich efﬁcacy and life expectancy in patients.
CABG is associated with many perioperative complications,
including supraventricular and ventricular arrhythmias and conduc-
tion disturbances.3,4 Arrhythmias are major complications after
cardiac surgery, and can lead to morbidity and mortality, increased
length of hospital stay and economic expenses.3,5
Various medications have been suggested to control arrhythmias.
In some cases, antiarrhythmic drugs or electrical cardioversion
could be administered. Magnesium sulphate (MGS) solution has
been used as an adjuvant medication in anaesthesia for numerous
different purposes. It has been administered in surgical patients as
an analgesic and in cardiac operation patients as an anti-
inﬂammatory agent.6–9 It has been demonstrated that the adminis-
tration of MGS could decrease the incidence of post-operative atrial
ﬁbrillation (AF) in cardiac surgery patients.10–12
To date, there is no conclusive evidence about the effective-
ness of MGS on alleviating arrhythmias in patients who under-
went CABG surgery. Therefore, this study explores the possible
effects of MGS on reducing arrhythmias in patients
after CABG.
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Patients and methods
The controlled clinical trial enrolled 250 patients who underwent
CABG. The ethics committee of Human Research at Ardabil Uni-
versity of Medical Sciences (Human Bioethics Committee)
approved the study. Iranian Registry of Clinical Trials (IRCT),
which is one of the certiﬁed Primary Registries in the WHO Regis-
try Network, registered this clinical trial with the number of
‘IRCT2015092224133N1’. Moreover, all patients gave an informed
written consent before enrolment.
Based on the initial blood level of magnesium, patients were
allocated into one of the two groups of hypomagnesium and nor-
momagnesium. According to recommendations of IRCT and also
requirements from Human Bioethics Committee, hypomagnesium
patients should have normal blood level of magnesium before
undergoing cardiac operation. Therefore, in order to fulﬁl the
requirements and comply with human bioethics criteria, patients in
the hypomagnesium group received MGS to attain normal blood
level of magnesium (1.7–2.2 mg/dL).
Both groups underwent surgery with normal blood levels of
magnesium. In order to elucidate the efﬁcacy of post-operative
magnesium therapy on the incidence of cardiac arrhythmias after
CABG, both groups should be divided into two: placebo and MGS-
administered subgroups.
Therefore, after surgery, both groups were randomly divided into
two subgroups: subgroup #1 (placebo subgroup) received a normal
saline with the same volume and the same infusion model as treat-
ment, and subgroup #2 (MGS subgroup) received a bolus dose of
MGS (30 mg/kg in 5 min).
The blood samples of patients were collected and each patient
was given a speciﬁc code.
One of the project team members gathered the data from patients
in the intensive care unit; she was blinded regarding the categoriza-
tion of groups and subgroups. Subgroups were under observation
for 3 days in the intensive care unit and arrhythmias were recorded.
Statistical analysis
Statistical analysis was performed using a graph and data analysis
software package (SigmaPlot 12.0, Systat Software, Inc., San Jose,
CA, USA). Data are presented as mean  SD, except in ﬁgures
where error bars represent SEM. Analysis of variance tests followed
by chi-square test for multiple comparisons were performed to check
the differences. P-value <0.05 was considered signiﬁcant.
A power calculation was done to ascertain whether sufﬁcient
numbers of patients would make signiﬁcant difference between the
groups. The calculation estimated that a sample size of 55 patients
in each group completing the study would allow us to detect a sig-
niﬁcant difference with 95% power with an alpha value of 0.05
(a 5% chance of incorrectly accepting the hypothesis).
Results
Demographic variables (including gender, age, body mass, serum
creatinine, history of previous diabetes, β-blockers therapy, diuretic
therapy and antiarrhythmia therapy) were measured and analysed in
hypo- and normo-magnesium groups. There was no recorded case
of mortality or morbidity in the two groups of patients in this study.
There were no signiﬁcant differences between the two groups with
regard to preoperative parameters (Table 1). Serum levels of elec-
trolytes were between the normal ranges during the study.
Serum magnesium levels of the patients in the four subgroups
were analysed and compared with each other (Table 2). There was
no signiﬁcant difference between subgroups in 24, 48 and 72 h
time points after operation.
Patients were monitored and prevalence of arrhythmias was
recorded for 3 days after CABG. Because of high incidence of AF
and premature ventricular contractions, these were reported sepa-
rately. However, other types of arrhythmia were documented as
one category (Table 3).
The incidence of arrhythmias was measured for the period of 3 days
after surgery. Based on chi-square test, there was no signiﬁcant differ-
ence between subgroups in three time points (P > 0.05, Table 4).
In order to elucidate the relevance of blood magnesium with the
incidence of arrhythmias, serum levels of magnesium were meas-
ured at three time points after surgery (Table 5).
Discussion
MGS inhibits the release of catecholamines from adrenal medulla
and peripheral nerve endings and directly blocks receptors of cate-
cholamines.13 Therefore, MGS causes sympathetic block which
causes dilated blood vessels and, consequently, reduces blood
pressure.14–17 It has been reported that administration of MGS solu-
tion could suppress part of the inﬂammatory response after
CABG.18,19 Another study has demonstrated that intravenous MGS
could decrease the serum levels of post-operative N-terminal pro-
brain natriuretic peptide in elective CABG.20 MGS might be
Table 1 Demographics and characteristics
Variable Hypomagnesium Normomagnesium P-value
Age (years old) 60.8  7.6 61.3  6.6 0.41
Male 64.5 58.6 0.72
Female 35.5 41.4 0.65
Cardiac cachexia 16.5 17.8 0.86
History of previous diabetes 35.3 10.6 0.56
Serum creatinine 1.2  0.5 1.2  0.3 0.47
β-Blockers therapy 71.6 69.4 0.51
Diuretic therapy 62.8 60.4 0.84
Antiarrhythmia therapy 25.5 25.5 0.5
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effective in regulating haemodynamics, while it may increase the
heart rate.21 It is considered as a medication for the treatment of
pre-eclampsia and blood pressure management.22–24
To date, there is no consensus protocol in administration of
MGS to prevent the incidence of cardiac arrhythmias after CABG.
The discrepancy between surgeons may in part be due to implica-
tion of different methods of MGS administration.
Even though it has been suggested that N-acetylcysteine and
magnesium decreased pump-induced oxidative stress during cardio-
pulmonary bypass,10,25 our data suggest that MGS might not have
any effect in reducing post-operative arrhythmias.
Our results demonstrated that there were no differences in the
incidence of arrhythmias at three time points after CABG. Adminis-
tration of MGS did not improve the occurrence of arrhythmias in
hypomagnesium patients for whom serum magnesium levels were
adjusted before operation, or in normomagnesium patients who
needed no serum magnesium adjustment before surgery. Moreover,
there was no signiﬁcant correlation between post-operative serum
levels of magnesium and arrhythmia during 3 days (P > 0.05).
Results of several studies are in agreement with our ﬁndings.
Outcomes of a randomized clinical trial revealed that prophylactic
intravenous MGS in addition to oral β-blockade did not prevent
atrial arrhythmias after coronary artery or valvular heart surgery.26
A report that is published in the Cochrane Database Systematic
Reviews analysed the data from 118 randomized controlled trials.
Analysed interventions included amiodarone, beta-blockers, sotalol,
magnesium, atrial pacing and posterior pericardiotomy. These inter-
ventions were effective in reducing the rate of post-operative AF
after cardiac surgery compared with a control. However, magne-
sium’s efﬁcacy reported to be slightly less.27 Another meta-analysis
that focused on well-conducted, ﬁve double-blind, intention-to-treat
studies showed that the prophylactic use of magnesium did not pre-
vent post-operative AF.28
Interestingly, another meta-analysis suggested that magnesium
had no effect on the incidence of post-operative stroke, myocardial
infarction and death. Moreover, it mentions that magnesium did not
decrease the hospital or intensive care unit lengths of stay. This
study suggested that in higher quality studies MGS did not reduce
post-operative supraventricular arrhythmias signiﬁcantly.29
In contrast, a meta-analysis study of 2490 patients reported that
magnesium administration reduced the incidence of developing
post-operative AF from 28% in the control group to 18% in the
treatment group; however, it did not signiﬁcantly decrease hospital
length of stay or mortality.30 However, another meta-analysis
revealed that magnesium administration is not effective for redu-
cing post-operative atrial arrhythmias, hospital length of stay and
Table 2 Serum magnesium levels in hypo- and normo-magnesium groups and relevant subgroups (mean  SD)
Hypomagnesium P-value Normomagnesium P-value
Placebo Prophylaxis Placebo Prophylaxis
First day 1.82  0.14 2.36  0.12 0.001 1.75  0.18 2.15  0.21 0.001
Second day 1.67  0.14 2.24  0.13 0.001 1.62  0.19 2.92  0.25 0.001
Third day 1.45  0.15 2.08  0.14 0.001 1.45  0.17 2.76  0.22 0.001
Table 3 Incidence of arrhythmias at three time points after CABG. Because of high incidence of AF and PVCs, these are reported separately
Day 1 Day 2 Day 3
Without arrhythmia 178 (71.2%) 184 (73.6%) 167 (66.8%)
AF 40 (16%) 41 (16.4%) 48 (19.2%)
PVCs 28 (11.2%) 23 (9.2%) 30 (12%)
Other arrhythmias 4 (1.6%) 2 (0.8%) 5 (2%)
AF, atrial ﬁbrillation; CABG, coronary artery bypass grafting; PVC, premature ventricular contraction.
Table 4 Comparison of arrhythmia incidence in different subgroups at three time points after CABG. Data are presented as percentile of the patients in
each subgroup at speciﬁc time point
Arrhythmia incidence Hypomagnesium Normomagnesium P-value
Placebo Prophylaxis Placebo Prophylaxis
Day 1 + 37.4 21 32.5 16.9 0.38
− 62.6 79 67.5 83.1 0.45
Day 2 + 29.2 27.8 22.9 20 0.72
− 70.8 72.2 77.1 80 0.23
Day 3 + 40.8 31.3 33.6 24.4 0.69
− 59.2 68.7 66.4 75.6 0.45
CABG, coronary artery bypass grafting.
Table 5 Serum magnesium (mg/dL) levels after CABG (mean  SD)
Serum magnesium Without arrhythmia Arrhythmias P-value
Day 1 2.35  0.7 2.15  0.8 0.22
Day 2 2.19  0.8 2.07  0.7 0.92
Day 3 1.96  0.6 1.8  0.5 0.78
CABG, coronary artery bypass grafting.
© 2017 Royal Australasian College of Surgeons
Effect of magnesium on arrhythmia 3
mortality after CABG.31 These reports support our ﬁndings and add
evidence against the prophylactic administration of magnesium for
prevention of arrhythmias after CABG.
Conclusion
The results of this clinical trial add evidence against the effective-
ness of MGS for prevention of arrhythmias after CABG. The inci-
dence of arrhythmias in MGS-administered subgroups was not
signiﬁcantly different from placebo-administered subgroups. There
was no signiﬁcant correlation between serum levels of magnesium
and arrhythmia during 3 days post-operation.
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